QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-maintains-neutral-on-virios-therapeutics-lowers-price-target-to-02

HC Wainwright & Co. analyst Sean Lee maintains Virios Therapeutics (NASDAQ:VIRI) with a Neutral and lowers the price tar...

 virios-therapeutics-q2-2024-gaap-eps-005-inline

Virios Therapeutics (NASDAQ:VIRI) reported quarterly losses of $(0.05) per share which met the analyst consensus estimate. This...

 maxim-group-initiates-coverage-on-virios-therapeutics-with-buy-rating-announces-price-target-of-1

Maxim Group analyst Jason McCarthy initiates coverage on Virios Therapeutics (NASDAQ:VIRI) with a Buy rating and announces P...

 virios-therapeutics-inc-to-offer-85m-shares-of-common-stock-at-020-per-share

- SEC Filing

 reported-earlier-virios-therapeutics-prices-17m-public-offering-of-85m-common-stock-to-commence-preparations-for-planned-imc-2-long-covid-phase-2b-study-at-020share

Virios Therapeutics, Inc. (NASDAQ:VIRI) (the "Company" or "Virios Therapeutics"), a development-stage biotechno...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION